Anti-SIRP alpha/beta dual antibody - Aurigene Oncology
Alternative Names: Research programme: anti-SIRPα/β dual antibodies - Aurigene OncologyLatest Information Update: 10 Jul 2024
Price :
$50 *
At a glance
- Originator Aurigene Oncology
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action CD47 antigen inhibitors; SIRPA protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer